SEC Form 4 · accession 0001140361-17-045018
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Debanjan Ray
Officer — Chief Financial Officer
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 12:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2017 | A | 163 | $12.1465 | A | 12,289 | D | |
| Common Stock | Dec 1, 2017 | S | 2,500 | $20.58 | D | 9,789 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1163 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.